Remo Panaccione, MD

University of Calgary, Canada

Poster(s):

• P3631 - Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT

• P3632 - Tofacitinib for the Treatment of Ulcerative Colitis: Up to 9.2 Years of Safety Data from the Global Clinical Program
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT

• P3633 - Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Communication Relating to Ulcerative Colitis Symptoms in Canada
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT